A Phase 2 interventional study of Oleogel-S10 100 mg/g and Placebo (petroleum jelly) in Actinic Keratoses, sponsored by Birken AG. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-14.
Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Keratosis, Actinic with a site in Germany — 4 open to participants now, 6 under way, 1 of them phase 3. Keratosis, Actinic · Germany.
Among the 53 studies in Keratosis, Actinic with a site in Germany, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2008, is one of 11 in phase 2, and was the 9th registered.
343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.
Browse Keratosis, Actinic studies →4 of the 53 studies in Keratosis, Actinic with a site in Germany are open now. Recruiting first, the newest first:
Thomas Dirschka · Sites in Germany
Ages 18+
Aresus Pharma GmbH · Sites in Germany
Ages 18+
CentroDerm GmbH · Sites in Germany
Ages 18+
Cosmetique Active International · Sites in Germany
Ages 18+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 137 across the 45 interventional studies, 73 across the 7 observational. Of the 44 that completed or were terminated, 16 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 53 have an industry lead sponsor. The 10 most frequent:
This study is registered under Birken AG, one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
Birken AG is the lead sponsor of 6 studies on the registry; none are open to participants now.
Chiesi Farmaceutici S.p.A. has 1 study filed under Keratosis, Actinic — fewer than ten, so there is no comparison to draw.
1 of the studies in Keratosis, Actinic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05387525Almirall, S.A.A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Keratosis, Actinic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study the impact of Oleogel-S-10 versus placebo on actinic keratoses over a treatment period of 3 months will be tested. Additionally, once and twice daily applications are tested.
Oleogel-S-10 has shown efficacy and was well tolerated in two previous clinical trials. In the second open label phase II trial the efficacy of Oleogel-S-10 alone was similar compared to a more invasive treatment with cryotherapy. Response rates of 85% with a clear-ance of more than 75 % of the lesions of the patients treated with Oleogel-S-10 over three months were reported. These encouraging results led to the present randomized, multicenter, double blind phase II trial. The efficacy of the treatment shall be tested in a double blind placebo controlled (petroleum jelly) fashion in order to obtain more reliable results for the planning of a phase III study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Actinic keratoses with a diameter of 0,5 - 2 cm,
In case of females: defined as
prepared and comply with all study requirements, including the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
Drug: Oleogel-S10 100 mg/g
Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
Drug: Oleogel-S10 100 mg/g
Placebo (petroleum jelly) for three months once a day (27 patients)
Drug: Placebo (petroleum jelly)
Placebo (petroleum jelly) for three months twice a day (27 patients)
Drug: Placebo (petroleum jelly)
Drug pages: Episalvan · Birch triterpenes
topical use once or twice daily
topical use once or twice daily
Also known as: Vaseline
Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance.
Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy. The Cockerell classification refers to a single lesion, graded as the presence of atypical cells in the lower third of the epidermis (grade I), involvement of at least the lower two-thirds (grade II) or atypical keratinocytic proliferation in the entire epidermis (grade III). Thus a down-grading from a higher Cockerell grade (e.g., III) to a lower Cockerell grade (e.g., I) represents a positive outcome and treatment success.
Time frame: 18 weeks
165 patients were recruited.
| Milestone | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C - Placebo Once Daily | D - Placebo Twice Daily |
|---|---|---|---|---|
| Started | 57 | 54 | 26 | 28 |
| Itt | 53 | 51 | 25 | 28 |
| Completed | 47 | 39 | 24 | 22 |
| Not completed | 10 | 15 | 2 | 6 |
Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy. The Cockerell classification refers to a single lesion, graded as the presence of atypical cells in the lower third of the epidermis (grade I), involvement of at least the lower two-thirds (grade II) or atypical keratinocytic proliferation in the entire epidermis (grade III). Thus a down-grading from a higher Cockerell grade (e.g., III) to a lower Cockerell grade (e.g., I) represents a positive outcome and treatment success.
| participants | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C/D - Placebo Once or Twice Daily |
|---|---|---|---|
| Success: Downgrading or clearance | 22 | 17 | 19 |
| Failure: No downgrading or clearance | 25 | 22 | 27 |
Collected over Treatment period of 18 weeks: Visits at 0, 6, 12 and 18 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A - Oleogel-S10 Once Daily | — | 2/57 (3.5%) | 3/57 (5.3%) |
| B - Oleogel-S10 Twice Daily | — | 3/54 (5.6%) | 7/54 (13%) |
| C - Placebo Once Daily | — | 0/26 (0%) | 3/26 (11.5%) |
| D - Placebo Twice Daily | — | 0/28 (0%) | 3/28 (10.7%) |
| Event | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C - Placebo Once Daily | D - Placebo Twice Daily |
|---|---|---|---|---|
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 1/54 | 0/26 | 0/28 |
| Prolaps of intervertebral discMusculoskeletal and connective tissue disorders | 0/57 | 1/54 | 0/26 | 0/28 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 1/54 | 0/26 | 0/28 |
| Fracture of ribInjury, poisoning and procedural complications | 1/57 | 0/54 | 0/26 | 0/28 |
| Respiratory infectionInfections and infestations | 1/57 | 0/54 | 0/26 | 0/28 |
| Event | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C - Placebo Once Daily | D - Placebo Twice Daily |
|---|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 1/54 | 0/26 | 2/28 |
| RashSkin and subcutaneous tissue disorders | 0/57 | 3/54 | 1/26 | 0/28 |
| PruritusSkin and subcutaneous tissue disorders | 0/57 | 1/54 | 1/26 | 0/28 |
| Allergic reaction/hypersensitivity (including drug fever)Immune system disorders | 0/57 | 0/54 | 1/26 | 0/28 |
| Flu-like syndromeInfections and infestations | 0/57 | 2/54 | 0/26 | 1/28 |
| Gastritis (including bile reflux gastritis)Gastrointestinal disorders | 2/57 | 0/54 | 0/26 | 0/28 |
| Cough / upper respiratory tract infectionInfections and infestations | 2/57 | 0/54 | 0/26 | 0/28 |
ITT
| Age, Continuous(years) | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C - Placebo Once Daily | D - Placebo Twice Daily | Total |
|---|---|---|---|---|---|
| Median | 72 (61 to 88) | 74 (56 to 85) | 69 (57 to 81) | 72 (51 to 83) | 72 (51 to 88) |
| Sex: Female, Male(Participants) | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C - Placebo Once Daily | D - Placebo Twice Daily | Total |
|---|---|---|---|---|---|
| Female | 41 | 42 | 20 | 25 | 128 |
| Male | 12 | 9 | 5 | 3 | 29 |
| Actinic keratosis baseline severity index(participants) | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C - Placebo Once Daily | D - Placebo Twice Daily | Total |
|---|---|---|---|---|---|
| Mild | 22 | 18 | 9 | 13 | 62 |
| Moderate | 31 | 33 | 16 | 15 | 95 |
| Histopathological grading(participants) | A - Oleogel-S10 Once Daily | B - Oleogel-S10 Twice Daily | C - Placebo Once Daily | D - Placebo Twice Daily | Total |
|---|---|---|---|---|---|
| Grade I | 9 | 4 | 2 | 2 | 17 |
| Grade II | 11 | 10 | 4 | 12 | 37 |
| Grade III | 32 | 36 | 19 | 13 | 100 |
| not done | 1 | 1 | 0 | 1 | 3 |
The record gives a start of Oct 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Episalvan · Birch triterpenes